PTK2 and neoplasm: Additionally, ITGA5 promotes tumor cell adhesion and migration through activating focal adhesion kinase (FAK), and an antibody (Volociximab) or a non–RGD-based peptide inhibitor (ATN-161), which blocks the function of the heterodimer function, significantly inhibits the growth and metastasis of breast cancer cells [23, 34].